文献速递冠心病

冠心病患者停用阿司匹林的证据与实践考量

Aspirin Withdrawal in Patients With Coronary Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2026-07-15

该文围绕冠心病二级预防中停用阿司匹林的策略进行综述,评估在急性冠脉综合征或经皮冠状动脉介入治疗后短期联合抗栓后撤除阿司匹林的药理学依据、临床试验证据与指南推荐。结论认为停用阿司匹林的获益与风险因临床场景、患者特征、停药时机及替代抗栓方案而异。

要点

  • 冠心病合并口服抗凝适应证者,阿司匹林联合口服抗凝增加出血且无缺血获益。
  • 急性冠脉综合征或经皮冠状动脉介入治疗后短期联合抗栓再停用阿司匹林是可选策略。
  • 停用阿司匹林的疗效与安全性取决于临床场景、患者特征和替代抗栓方案。

核心结论

  • 停用阿司匹林的疗效与安全性因临床场景、患者特征、停药时机及替代抗栓治疗不同而有显著差异。

研究设计与样本

  • 该文为叙述性综述,回顾阿司匹林停用的药理学依据、临床试验证据及指南推荐,并提出实践考量。

主要发现

  • 冠心病合并口服抗凝适应证的患者中,阿司匹林联合口服抗凝增加出血风险且未带来缺血获益。
  • 急性冠脉综合征或经皮冠状动脉介入治疗后短期联合抗栓再停用阿司匹林被认为是有吸引力的策略。
  • 出血对预后的不良影响推动了对降低出血且不损害缺血保护的抗栓方案的研究。

关键数值与推荐

  • 冠心病合并口服抗凝适应证的患者约占全部冠心病患者的15%。

临床怎么用

  • 临床决策应考虑临床场景、年龄、性别、种族、遗传背景、合并症、停药时机及P2Y12抑制剂选择等因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with coronary artery disease (CAD), aspirin has long represented the cornerstone of antiplatelet therapy for secondary prevention. In patients with an acute coronary syndrome (ACS) and undergoing percutaneous coronary intervention (PCI), oral P2Y12 inhibitors have traditionally been used as adjuncts to aspirin, a strategy known as dual antiplatelet therapy (DAPT). Although DAPT reduces the risk of ischemic recurrences, it carries a risk of bleeding. In CAD patients with a concomitant indication for oral anticoagulation (OAC)-who account for approximately 15% of patients--the combination of aspirin and OAC is associated with an increased risk of bleeding without ischemic benefit. The adverse impact of bleeding on prognosis has prompted investigations aimed at identifying antithrombotic treatment regimens associated with reduced bleeding without compromised ischemic protection. Among these, a strategy of aspirin withdrawal after a brief period of combination therapy has emerged as an attractive option. The efficacy and safety of aspirin withdrawal, however, vary substantially according to clinical setting, patient profile (eg, age, sex, ethnicity, genetic background, and comorbidities), timing of discontinuation after ACS or PCI, and alternative adjunctive antithrombotic therapy, including use of OAC and choice of P2Y12 inhibitor. After reviewing the pharmacologic rationale for aspirin withdrawal, the clinical trial evidence, and guideline recommendations, we provide practical considerations for the implementation of this strategy in patients with CAD, with and without an indication to be on OAC.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Galli, Capodanno, Berg, et al. Aspirin Withdrawal in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2026. PMID: 42455105. doi:10.1016/j.jacc.2026.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。